MDL | MFCD04039839 |
---|---|
Molecular Weight | 1031.18 |
Molecular Formula | C51H82O21 |
SMILES | C[C@@]1([C@](C(C)=C(CC[C@@H](C)CO[C@@H]([C@@H]([C@@H](O)[C@@H]2O)O)O[C@@H]2CO)O3)([H])[C@]3([H])C4)[C@]4([H])[C@@](CC=C5[C@@]6(CC[C@H](O[C@@](O[C@H](CO)[C@@H](O[C@@](O[C@@H](C)[C@H](O)[C@H]7O)([H])[C@@H]7O)[C@@H]8O)([H])[C@@H]8O[C@@](O[C@@H](C)[C@H](O)[C@H]9O)([H])[C@@H]9O)C5)C)([H])[C@]6([H])CC1 |
Pseudoprotodioscin, a furostanoside, inhibits SREBP1/2 and microRNA 33a/b levels and reduces the gene expression regarding the synthesis of cholesterol and triglycerides [1] .
In Hep G2 cells, Pseudoprotodioscin increases ABCA1 protein and mRNA levels, and promotes the effluxion of ApoA-1-mediated cholesterol. Pseudoprotodioscin inhibits SREBP1c and SREBP2 transcription by decreasing microRNA 33a/b levels. This procedure reciprocally lead to the increase of ABCA1 levels. In THP-1 macrophages, Pseudoprotodioscin shows the similar effect, which reduces HMGCR, FAS and ACC mRNA levels and promotes low density lipoprotein receptor by decreasing the PCSK9 levels [1] .
MCE has not independently confirmed the accuracy of these methods. They are for reference only.
Solid
Room temperature in continental US; may vary elsewhere.
-20°C, protect from light
* In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)
H 2 O : ≥ 100 mg/mL ( 96.98 mM )
DMSO : 100 mg/mL ( 96.98 mM ; Need ultrasonic)
* "≥" means soluble, but saturation unknown.
Concentration Solvent Mass | 1 mg | 5 mg | 10 mg |
---|
1 mM | 0.9698 mL | 4.8488 mL | 9.6976 mL |
5 mM | 0.1940 mL | 0.9698 mL | 1.9395 mL |
10 mM | 0.0970 mL | 0.4849 mL | 0.9698 mL |